Stocktoria
AbbVie Inc. ABBV
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2013-01-02
AbbVie Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $61.2B | $56.3B | $54.3B | $58.1B | $56.2B |
| SG&A expense | $14.0B | $14.8B | $12.9B | $15.3B | $12.3B |
| Operating income | $15.1B | $9.1B | $12.8B | $18.1B | $17.9B |
| Interest expense | $2.9B | $2.8B | $2.2B | $2.2B | $2.4B |
| Income tax | $2.4B | -$570.0M | $1.4B | $1.6B | $1.4B |
| Net income | $4.2B | $4.3B | $4.9B | $11.8B | $11.5B |
| EPS (diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Operating cash flow | $19.0B | $18.8B | $22.8B | $24.9B | $22.8B |
| Free cash flow | $17.8B | $17.8B | $22.1B | $24.2B | $22.0B |
| Cash & equivalents | $5.2B | $5.5B | $12.8B | $9.2B | $9.7B |
| Inventory | $5.0B | $4.2B | $4.1B | $3.6B | $3.1B |
| Total assets | $134.0B | $135.2B | $134.7B | $138.8B | $146.5B |
| Shareholders' equity | -$3.3B | $3.4B | $10.4B | $17.3B | $15.4B |
Source: SEC EDGAR filings · CIK 0001551152 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.